Latest Australian Securities News

Lendlease Corporation has released its full year financial results for 2025, accompanied by the detailed Final Report. Investors await insights beyond the headline announcement to gauge the company’s trajectory.

DigiCo Infrastructure REIT, newly listed on the ASX, posted a $67.9 million loss for its inaugural period ending June 2025, reflecting significant acquisition and IPO costs amid rapid expansion in data centre assets.

The Federal Court has approved Platinum Asia Investments' scheme to convert shares into ETF units, marking a significant restructuring for shareholders. Key dates for trading suspension, valuation, and dividend payments are set for August.

Adriatic Metals shareholders have overwhelmingly approved Dundee Precious Metals’ recommended acquisition scheme, clearing a major hurdle toward completion. Key regulatory approvals are in place, with the final court sanction hearing scheduled for late August.

My Rewards International is seeking shareholder approval to convert $2.2 million of debt into equity and launch a $3.98 million entitlement offer, key steps toward regaining its ASX listing.

Xstate Resources has secured over $2 million from more than 300 new investors in its Re-compliance Prospectus offer, positioning itself for a potential return to ASX trading by early September.

BPH Energy has responded to an ASX price query following unusual trading activity, confirming no undisclosed information exists and pointing to ongoing legal matters involving its investee Advent Energy as context.

Robex Resources Inc. reported a challenging Q2 2025 with a significant net loss driven by legal settlements and subsidiary dissolution, yet it progresses steadily on its Kiniéro Gold Project with strong backing from its recent ASX IPO and Sprott financing.

Robex Resources Inc reported a substantial net loss for the first half of 2025, reflecting operational challenges and legal settlements, while advancing financing and construction of its key Kiniéro gold project in Guinea.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

ASX Limited reported a solid FY25 financial performance with a 7.5% rise in underlying net profit and a higher fully franked dividend, while advancing its CHESS replacement project amid ongoing regulatory scrutiny.

ASX Limited reported a robust FY25 with revenue and underlying profit growth, while navigating regulatory scrutiny following a major settlement incident. The company advances its technology transformation and sustainability agenda as it seeks to rebuild trust and deliver shareholder value.